-
- 1800 2010
- EN
-1366x0.jpg)
News
Array
(
[0] => stdClass Object
(
[id] => 1286
[id_crawler] =>
[category_product] => NULL
[thumbnail] => dsc02895.jpg
[album] =>
[url_video] =>
[is_status] => 1
[is_featured] => 0
[is_form] => 0
[displayed_time] => 2025-03-14
[program] => 0
[number] => 1
[viewed] => 0
[type] =>
[type_career] =>
[level] =>
[address] =>
[address_career] =>
[expiration_time] => 0000-00-00
[created_time] => 2025-03-14 09:09:13
[updated_time] => 2025-03-14 15:58:11
[files] =>
[salary] =>
[time] =>
[created_by] => 63
[is_table_content] => 1
[language_code] => en
[slug] => https://gentis.com.vn/tin-tuc-c4/gentis-tiep-don-doan-chuyen-gia-illumina-den-tham-quan-va-lam-viec-d1286
[title] => GENTIS welcomes Illumina experts to visit and work
[description] => On March 13, GENTIS was honored to welcome Illumina experts to visit and work in Hanoi. The delegation was led by Ms. Katie Battese Ellis - Senior Director, Medical Affairs of Illumina in charge of several countries in the APAC region, along with Illumina experts in Vietnam.
[content] => 
GENTIS representatives welcomed the delegation with Mr. Do Manh Ha - General Director, Dr. Pham Dinh Minh - Director of R&D and related departments/offices. At the meeting, the delegation visited the office area, the international standard GENTIS Eurofins Laboratory and shared experiences and genetic knowledge with GENTIS. Accordingly, Ms. Katie highly appreciated the design, equipment, and machinery of GENTIS's lab and hoped to have more opportunities to accompany the company.
GENTIS believes that Illumina - the world's leading Biotechnology group in human health and genomics, a pioneer in innovating the future of precision health, will be a reliable and long-term partner, helping GENTIS develop rapidly and sustainably in the future! As a partner of Illumina in Vietnam, GENTIS will continue to conquer new applications and technologies to bring more value to customers and patients, with the ambition to pioneer becoming a unit with a comprehensive genetic ecosystem.
With 15 years of experience in building and operating a modern Genetic Testing Center, GENTIS is ready to welcome domestic and foreign medical units to visit, share, exchange experiences, and learn to improve the quality of testing to serve doctors in accurate diagnosis, effective treatment for patients, as well as better health care for people every day. GENTIS Hanoi is proud to own a modern LAB, surpassing many strict domestic and international quality standards:
- Area up to 2,000m2
- Located in the city center, convenient transportation
- GENTIS Eurofins laboratory system meets ISO 9001:2015, ISO 15189:2022, ISO 13485:2016, ISO/IEC 27001:2022 standards and aims for CAP standards
- Leading technology equipment from the US, Europe, Korea... such as: New generation sequencing NGS; iScan system; Realtime PCR technique; Sanger sequencing; Flow Cytometry Technique
- Process of testing in a professional lab, ensuring accuracy
- Highly specialized R&D team
- Technical team for sample collection and testing are well-trained and specialized
The 7th Tzu Chi - Academia Sinica Biomedical Conference
The 7th Tzu Chi - Academia Sinica Biomedical Conference 2025 was held at Tzu Chi University, Hualien City, Taiwan. This year's conference focused on the theme of “Applications of AI in Biomedical Research” and “Multidisciplinary Perspectives in Biomedical Research & Therapy”.
Dr. Pham Dinh Minh - Director of R&D GENTIS (standing in the middle) with experts at Tzu Chi University
The conference brings together leading scientists and experts in the field of biomedical science in the world from the US, Japan, Korea, Vietnam, Thailand, Indonesia, Philippines, etc. The conference provides delegates as well as the community developing artificial intelligence in medicine in general, biomedicine in particular, with the latest research and development as well as the market in the field of research and application of AI.
Report by Dr. Pham Dinh Minh at the 7th Tzu Chi - Academia Sinica Biomedical Conference
The application of genetic and genomic testing is booming in the healthcare sector in Vietnam. Recently, we have witnessed the rapid application of tests in many healthcare areas, such as reproductive health, obstetrics and gynecology, newborn screening, cancer and cardiovascular diseases…
As we know, the development of AI has attracted many people, especially those working in the field of research and development. For the general community, the development of AI tools such as China's Deepseek or xAI's Grok has greatly changed the development as well as the application in social life.
Dr. Minh presented the report "Development and application of AI/Bioinformatics in genetic and genomic testing in Vietnam"
In the medical field, although still very new, AI has also been developed. In Vietnam, there are very good potentials, especially the amount of data, the huge amount of data related to health and testing. In particular, GENTIS is one of the large testing units and has a huge amount of data in Vietnam about genetic testing, gene testing. This is one of the advantages of GENTIS to be able to apply to develop as well as research AI in the testing field.
At the 7th Tzu Chi - Academia Sinica Biomedical Conference, the report on the topic "Development and application of AI/Bioinformatics in genetic and gene testing in Vietnam" by Dr. Pham Dinh Minh (Director of R&D GENTIS - Director of GENTIS Genetic Counseling Center) attracted the attention of many attending experts. In the report, Dr. Pham Dinh Minh shared research and applications of AI and bioinformatics in genetic and gene testing, aiming to develop new tests and improve the quality of testing. Especially genetic testing in pre-implantation embryo screening, genetic testing in non-invasive prenatal screening as well as other genetic and gene testing.
Dr. Minh received a certificate at the 7th Tzu Chi - Academia Sinica Biomedical Conference
In addition, the report also provides the conference, as well as the Asia-Pacific scientific community, with information on the development, research, and application of AI, as well as bioinformatics in Vietnam in general and the medical, genetic and genetic testing fields in Vietnam in particular.
GENTIS applies AI/bioinformatics software in genetic research and testing
“Developing AI applications/bioinformatics software is one of the key, main areas that GENTIS is oriented to develop in the coming time. GENTIS is looking forward to finding opportunities to cooperate with partners as well as developing further, researching and developing the latest directions of artificial intelligence applications as well as applying AI technology in genetic testing, genetic testing to bring new and improved tests, improving the quality of current tests”, Dr. Pham Dinh Minh shared more.
Currently, GENTIS has research projects and applications of artificial intelligence as well as bioinformatics in the field of genetic and genetic testing. Specifically, GENTIS is researching and developing AI tools, bioinformatics tools for embryo screening, improving the quality of pre-implantation genetic testing for embryos, and non-invasive prenatal screening NIPT.
Technological autonomy will help improve testing efficiency, optimize testing, improve testing quality, and use Vietnamese data. At the same time, it can help reduce testing costs, as well as bring different testing packages and testing features into GENTIS's current testing packages and testing services.
[content_more] => [meta_title] => Dr. Pham Dinh Minh reported at the 7th Tzu Chi - Academia Sinica Biomedical Conference [meta_description] => On March 8, 2025, Dr. Pham Dinh Minh gave a report at the 7th Tzu Chi - Academia Sinica Biomedical Conference at Tzu Chi University, Hualien, Taiwan. [meta_keyword] => gentis,Ai [thumbnail_alt] => [post_id] => 1284 [category_id] => 4 ) [2] => stdClass Object ( [id] => 1283 [id_crawler] => [category_product] => NULL [thumbnail] => 6fdf64481b82aadcf393.jpg [album] => [url_video] => [is_status] => 1 [is_featured] => 0 [is_form] => 0 [displayed_time] => 2025-03-11 [program] => 0 [number] => 1 [viewed] => 0 [type] => [type_career] => [level] => [address] => [address_career] => [expiration_time] => 0000-00-00 [created_time] => 2025-03-11 10:47:49 [updated_time] => 2025-03-12 15:11:13 [files] => [salary] => [time] => [created_by] => 63 [is_table_content] => 1 [language_code] => en [slug] => https://gentis.com.vn/tin-tuc-c4/xet-nghiem-sperm-dna-giai-phap-hieu-qua-giup-bac-si-chan-doan-vo-sinh-nam-d1283 [title] => Sperm DNA Test - An effective solution to help doctors diagnose male infertility [description] => In recent years, infertility has been increasing and tends to be younger in the age of the disease. Many statistics show that the cause of infertility due to men is about 40%, equivalent to the infertility rate in women. Therefore, Sperm DNA is considered an important test for doctors in diagnosing and developing the best treatment regimen for infertile men. [content] =>What is Sperm DNA test?
Sperm DNA is a test that quantifies the rate of broken sperm DNA based on the color change of the dye through the flow cytometry system (Analyzing up to 10,000 sperm). Therefore, Sperm DNA is used as an important additional test in predicting male fertility, supporting the determination of the cause of infertility.
GENTIS's Sperm DNA test helps doctors comprehensively assess the patient's sperm quality
This test helps doctors better screen for cases of unexplained infertility. From there, they can orient appropriate intervention treatment (choosing assisted reproductive methods) to shorten time, costs and increase the chance of having children for couples.
The significance of Sperm DNA testing for male doctors
In an interview, Associate Professor, Dr. Le Minh Tam (Hue University of Medicine and Pharmacy) said: “Male infertility is a matter of great concern recently. For a long time, the methods of assessing male infertility were mainly based on semen analysis. However, the semen analysis method only shows the quantity, mobility density, survival rate... but does not show the internal nature of the sperm. Therefore, tests that describe the nature of the internal nature of the sperm are very meaningful”.
Associate Professor, Dr. Nguyen Quang (President of the Vietnamese Society for Sexual Medicine) shared: “Testing for male infertility is very important. It helps male doctors know the specific causes of male infertility, thereby having a specific direction for treatment for patients”.
Understanding this, GENTIS has researched and launched the Sperm DNA test to support a comprehensive assessment of sperm quality. This is an extremely necessary test for male doctors because:
- Helps determine the cause of infertility in men in cases where the semen analysis results are normal.
- Explains the phenomenon of consecutive miscarriages, unexplained infertility and IVF failure in couples.
- Comprehensive assessment of sperm quality through Sperm DNA testing is extremely necessary to predict fertility and have the most appropriate intervention (choosing a reproductive support method).
Who needs to do the Sperm DNA test?
Sperm DNA testing helps determine the cause of male infertility in cases where the semen analysis results are normal
According to GENTIS experts, men should do Sperm DNA testing if they are in the following cases:
- Unexplained male infertility or the cause is unclear.
- Recurrent miscarriages.
- Clinical symptoms of varicocele.
- Lifestyle-related risk factors.
- Before or after failure of assisted reproductive methods (ART) such as IUI, IVF, ICSI.
- Recurrent miscarriages after ICSI.
GENTIS - The most prestigious Sperm DNA testing unit today
In Vietnam, GENTIS is increasingly affirming its pioneering position in the field of genetic analysis of male infertility by researching and developing new tests. Outstanding advantages of Sperm DNA testing at GENTIS are:
- Modern technology: Analysis on the Flow cytometry system (analyzing up to 10,000 sperm). The advantages of the Flow cytometry system are stability, accuracy and high performance in Sperm DNA testing
- Automated, fast process
- Result return time: 24 hours
- Cost: Most reasonable, bringing Sperm DNA testing to all men
With ISO standards and working processes along with a team of leading experts in genetics and highly specialized biotechnology, GENTIS is committed to providing customers with quality Sperm DNA testing, affordable prices, and the most professional services. In particular, Sperm DNA testing supports well in diagnosing genetic factors in male infertility, thereby helping doctors to develop appropriate treatment regimens, overcoming infertility in men.
GENTIS is a pioneer in the field of genetic analysis, specializing in providing tests with the highest accuracy
In addition to Sperm DNA, to evaluate and find the cause of male infertility, GENTIS also provides many specialized tests to help doctors provide appropriate treatment. These include Karyotype testing, hormone testing, sperm DNA fragmentation, AZF testing, anti-sperm antibody testing, sperm chromosome aneuploidy testing, STDs testing, etc.
With a team of leading experts in genetics and biotechnology with high professional qualifications and the most modern facilities and technology, GENTIS is committed to providing tests with the highest accuracy. Thereby contributing to realizing the dream of becoming parents of infertile couples.
[content_more] => [meta_title] => Sperm DNA Test - An effective solution to help doctors diagnose male infertility [meta_description] => Sperm DNA is considered an important test for doctors in diagnosing and developing the best treatment regimen for infertile men. [meta_keyword] => gentis,sperm dna [thumbnail_alt] => [post_id] => 1283 [category_id] => 4 ) [3] => stdClass Object ( [id] => 1281 [id_crawler] => [category_product] => NULL [thumbnail] => af39d43f63cfdd9184de.jpg [album] => [url_video] => [is_status] => 1 [is_featured] => 0 [is_form] => 0 [displayed_time] => 2025-02-24 [program] => 0 [number] => 1 [viewed] => 0 [type] => [type_career] => [level] => [address] => [address_career] => [expiration_time] => 0000-00-00 [created_time] => 2025-02-24 09:14:22 [updated_time] => 2025-03-06 11:18:33 [files] => [salary] => [time] => [created_by] => 63 [is_table_content] => 1 [language_code] => en [slug] => https://gentis.com.vn/tin-tuc-c4/me-bau-nao-nen-thuc-hien-xet-nghiem-sang-loc-truoc-sinh-nipt-d1281 [title] => Which pregnant women should do Non-invasive prenatal testing? [description] => NIPT (Non-invasive prenatal testing) is a method of prenatal screening for pregnant women before giving birth. This prenatal screening method is often chosen because of its non-invasive advantages, helping to detect many congenital malformations in the fetus early, thereby helping pregnant women to manage their pregnancy effectively. [content] =>Who is NIPT suitable for?
With the common mentality of pregnant women being worried about the development and wanting the best care for the fetus, pregnant women always want to look for prenatal testing methods to check the health of the fetus. NIPT testing is recommended for pregnant women in the first 3 months and the middle 3 months of pregnancy, especially for those at high risk:
Pregnant women over 35 years old
According to research by experts, the quality of eggs in women after 35 years old decreases, directly affecting the embryo. Therefore, the fetus is at high risk of chromosomal disorders and is at risk of Down's, Edward's, Patau's syndrome...
In addition, women over 35 years old are often prone to problems such as uterine fibroids, endometriosis... when pregnant, their health declines, hormonal changes make the disease worse, leading to an increased risk of fetal malformations.
Family history of genetic diseases
Studies show that fetal malformations can be passed down from parents to children. If the family has parents-in-law, parents-in-law, or siblings with genetic diseases, the fetus is at high risk of malformations. Although there is no exact research on the percentage, pregnant mothers should also be screened before birth, especially by performing NIPT testing to be able to take good care of the fetus.
Pregnant women who undergo assisted reproductive techniques
The risk of birth defects in children born through artificial insemination is much higher than in children born naturally, even when maternal factors are controlled. Therefore, mothers who undergo this method are advised by doctors to use the NIPT test method.
Biochemical and ultrasound results - high-risk nuchal translucency measurement
History of pregnancy with malformations, unexplained stillbirths or giving birth to children with congenital malformations
Steps to perform NIPT testing
Step 1: Get advice from a doctor
Before taking a sample, the pregnant woman will be informed about the basic information of the NIPT test. Depending on the condition and finances of the pregnant woman, the doctor will advise on appropriate packages. Accompanying pregnant mothers on the path to reproductive health care, GENTIS provides a variety of NIPT prenatal screening service packages
- Genbasic
- Detects aneuploidy on 3 common chromosomes: Down, Patau, Edward
- Applicable for single and twin pregnancies
- Time to return results: 4 - 5 days
- Genbasic Plus
- Detects 5 syndromes: Edwards, Patau, Down, Turner (XO), Klinefelter (XXY)
- Applicable for single and twin pregnancies
- Time to return results: 4 - 5 days
- GenEva
- Detects 8 syndromes: Edwards, Patau, Down, Turner (XO), Klinefelter (XXY), trisomy (XXX), Jacobs (XYY) and detects quantitative abnormalities on all remaining chromosomes
- Applicable for single and twin pregnancies
- Time to return results: 4 - 5 days
- GenEva Plus
- Detects all all types of abnormalities in the GenEva package. At the same time, the package also detects 86 microdeletion mutations
- Applicable for single and twin pregnancies
- Time to return results: 4 - 5 days
Step 2: Take blood for NIPT screening test
Take 7-10ml of blood from the pregnant woman's arm vein for testing.
Step 3: Transfer the blood sample to the GENTIS testing center for analysis.
Step 4: Receive results after 4 - 5 days from the date of sample collection.
Step 5: After receiving the results, the doctor will analyze and advise on appropriate fetal care methods, especially in cases of genetic diseases.
Advantages of performing NIPT testing at GENTIS
High accuracy
NIPT testing is considered more accurate than traditional screening. NIPT prenatal screening is based on DNA genetic material, so it is not affected by environmental factors. In addition, the method is also performed by analyzing the new generation gene sequencing algorithm with a high-tech equipment system with an accuracy rate of over 99%.
Fast results
The test result return time is about 4 - 5 days after sample collection. The sample analysis time by machine is fast, helping NIPT test return results in the shortest time.
Safe
The test sample is the mother's blood, so the prenatal screening method does not cause any negative effects on both mother and baby. Because the test only takes 7-10ml of the mother's blood to separate extracellular DNA, then sequence the DNA and analyze.
Applicable in many cases
NIPT testing is applicable to cases of pregnant mothers with single, twin, and multiple pregnancies.
Screening and detecting diseases related to abnormal chromosomes is extremely good.
NIPT GENTIS test accompanies parents on the journey to welcome their beloved children. Contact hotline: 1800 2010 to schedule a consultation and NIPT test at GENTIS.
[content_more] => [meta_title] => Which pregnant women should do Non-invasive prenatal testing? [meta_description] => NIPT (Non-invasive prenatal testing) is a method of prenatal screening for pregnant women before giving birth. [meta_keyword] => gentis,Nipt [thumbnail_alt] => [post_id] => 1281 [category_id] => 4 ) [4] => stdClass Object ( [id] => 1280 [id_crawler] => [category_product] => NULL [thumbnail] => b1fcf6d2f5e24bbc12f3.jpg [album] => [url_video] => [is_status] => 1 [is_featured] => 0 [is_form] => 0 [displayed_time] => 2025-02-19 [program] => 0 [number] => 1 [viewed] => 0 [type] => [type_career] => [level] => [address] => [address_career] => [expiration_time] => 0000-00-00 [created_time] => 2025-02-19 10:58:57 [updated_time] => 2025-03-15 10:45:26 [files] => [salary] => [time] => [created_by] => 63 [is_table_content] => 1 [language_code] => en [slug] => https://gentis.com.vn/tin-tuc-c4/gentis-ra-mat-2-goi-xet-nghiem-phan-tich-di-truyen-truoc-chuyen-phoi-moi-pgt-next-va-pgt-upgrade-d1280 [title] => GENTIS launches 2 new test packages: PGT NEXT and PGT UPGRADE [description] => With the pioneering advantage in applying genetic and genetic testing in assisted reproduction, GENTIS constantly strives to improve and launch new expanded pre-implantation genetic testing packages: PGT NEXT and PGT UPGRADE. These are two superior in-depth integrated tests with many outstanding advantages. [content] =>
PGT NEXT
PGT NEXT is a pre-implantation genetic analysis test that can detect aneuploidy on 24 chromosomes, chromosomal abnormalities, and chromosomal deletions. It can also detect embryos with polyploidy or haploidy. This helps avoid transferring polyploid/haploidy abnormal embryos, and avoid wasting euploid embryos with fertilization abnormalities (0PN, 1PN, and 2.1/3PN). In addition, the PGT UPGRADE test also supports the provision of genetic information for embryo selection before embryo transfer. The combination of NGS whole genome sequencing with SNP analysis improves the resolution of genetic screening for polyploidy.This method allows for the identification of haploid and polyploid chromosome sets, increasing the number of healthy euploid embryos available for transfer by accurately detecting true diploid embryos among abnormally fertilized embryos (0PN, 1PN, 2.1PN, 3PN). Additionally, SNP analysis ensures precise identification of whether the tested embryo is genetically related to other embryos in the same cohort, thereby reducing the risk of sample mix-ups due to procedural or handling errors.
- Detection range:
- Aneuploidy of all 24 chromosomes
- Chromosomal structural abnormalities (addition, deletion)
- Detection of embryos with polyploidy or haploid abnormalities.
- Method: Whole genome sequencing and target marker sequencing on next-generation sequencing machine NGS.
- Sample used: Day 5 embryo biopsy sample
- Time to return results: 3 – 4 weeks
PGT UPGRADE
PGT UPGRADE is a pre-implantation genetic analysis test that can detect aneuploidy on 24 chromosomes, additional abnormalities, chromosomal deletions with a size of over 5 Mb, especially capable of detecting embryos carrying balanced translocations inherited from the parents. Chromosomal translocations are structural abnormalities of chromosomes caused by the rearrangement of large segments between non-homologous chromosomes. There are two types of translocations: balanced (no loss of genetic material) and unbalanced (loss or extra genetic material, such as aneuploidy). When both the father and mother carry balanced translocations, approximately 60% of gametes will carry unbalanced translocations, leading to embryos with chromosomal abnormalities. This is also a common cause of repeated implantation failure, recurrent miscarriage, and birth defects. PGT UPGRADE test helps to select euploid embryos for parents carrying balanced translocations to increase the chance of having a healthy baby. In addition, PGT UPGRADE also supports providing genetic information for the embryo selection process before embryo transfer.
Performing PGTest testing can select genetically good quality embryos to increase the chance of pregnancy when performing in vitro fertilization (IVF), helping to increase the chance of the child being born healthy, without the screened genetic abnormalities.
- Detection range:
- Aneuploidy of all 24 chromosomes
- Chromosomal structural abnormalities (addition, deletion) larger than 5 Mb
- Detection of embryos carrying balanced genetic translocations inherited from parents
- Method: Next generation sequencing NGS (Illumina) and analysis of sequencing results using specialized bioinformatics software
- Samples used:
- Parental samples (2-3 ml whole blood in EDTA anticoagulant tubes) and balanced translocation test results.
- Day 5 embryo biopsy sample
- Time to return results: 12 - 14 days
Meaning of PGT NEXT and PGT UPGRADE tests
Preimplantation Genetic Testing (PGT) is a specialized technique to identify genetic abnormalities in embryos created through in vitro fertilization (IVF/ICSI). Preimplantation genetic testing offers the following benefits:
Detecting genetic abnormalities in embryos
PGT helps identify abnormalities in chromosome number (PGT-A) or specific gene mutations (PGT-M), thereby reducing the risk of passing on genetic diseases to the next generation.
Increase IVF success rate
Selecting healthy embryos with normal genes improves implantation rates, increases the chance of pregnancy, and reduces the risk of miscarriage.
Support for optimal embryo selection
Ensuring that only embryos that do not carry genetic diseases or genetic abnormalities are transferred into the uterus increases the chances of having a healthy baby.
Advanced and modern technology
Illumina's next-generation sequencing technology (NGS) with >99% accuracy on target markers and specialized bioinformatics software is the technological standard for PGT testing, increasing the accuracy and sensitivity of the test.
Currently, preimplantation genetic testing (PGT) packages can be performed at a number of hospitals and reproductive support centers in Vietnam. Among them, GENTIS is a pioneer in performing PGT testing packages accurately and professionally.
In particular, GENTIS has a system of high-tech machinery and a team of experienced professionals, where infertile couples put their trust when performing difficult tests. Before doing the screening test, customers will be given genetic counseling and detailed information about the test. Through PGT testing packages, GENTIS hopes to support doctors and infertile couples to quickly find their beloved children, as well as give birth to healthy children, bringing happiness to families nationwide.
[content_more] => [meta_title] => GENTIS launches 2 new test packages: PGT NEXT and PGT UPGRADE [meta_description] => GENTIS constantly strives to improve and launch new expanded pre-implantation genetic testing packages: PGT NEXT and PGT UPGRADE. [meta_keyword] => gentis,Pgt,Pgtnext,Pgtupgrade [thumbnail_alt] => [post_id] => 1280 [category_id] => 4 ) [5] => stdClass Object ( [id] => 1275 [id_crawler] => [category_product] => NULL [thumbnail] => gentis-11.jpg [album] => [url_video] => [is_status] => 1 [is_featured] => 0 [is_form] => 1 [displayed_time] => 2025-01-14 [program] => 0 [number] => 1 [viewed] => 0 [type] => [type_career] => [level] => [address] => [address_career] => [expiration_time] => 0000-00-00 [created_time] => 2025-01-14 10:08:21 [updated_time] => 2025-01-14 10:16:28 [files] => [salary] => [time] => [created_by] => 63 [is_table_content] => 1 [language_code] => en [slug] => Breakthroughs-in-the-application-of-genetic-testing-in-reproductive-medicine-worldwide-and-in-Vietnam [title] => Breakthroughs in the Application of Genetic Testing in Reproductive Medicine Worldwide and in Vietnam [description] => During her visit and work in Vietnam, Assoc. Prof. Dr. Francesca Spinella (Senior Medical Information Specialist at Eurofins Genoma Group, Former President of ESHRE PGT Consortium) expressed her admiration for the remarkable advancements made by genetic testing laboratories in the diagnosis and treatment within the field of reproductive medicine. In particular, she praised GENTIS for both its professional expertise and state-of-the-art facilities. She mentioned that the collaboration between GENTIS and GENOMA will enhance multi-level development among global healthcare organizations, particularly in the area of genetic testing. [content] =>Genetic Breakthroughs in Preimplantation Genetic Testing Being Applied in Europe and Vietnam
Assoc. Prof. Dr. Francesca Spinella explained that there are currently three widely used preimplantation genetic testing techniques being applied across Europe and globally: PGT-A, PGT-SR, and PGT-M. These primary methods help improve the success rates of in vitro fertilization (IVF) while reducing the risk of serious genetic disorders in future generations.
Among these, PGT-A helps detect chromosomal aneuploidy to screen out embryos that have abnormalities. This method has been proven to increase IVF success rates, decrease miscarriage rates, and ensure that the embryos implanted are the healthiest.
PGT-M is used to detect genetic mutations that could be inherited from parents, helping to avoid passing on common monogenic disorders like thalassemia, cystic fibrosis, Huntington's disease, and other genetic conditions. PGT-SR can detect structural chromosome abnormalities such as translocations, inversions, or deletions. These abnormalities can cause pregnancy complications and increase the risk of giving birth to a child with birth defects.
In addition to the widely implemented techniques, Assoc. Prof. Dr. Francesca Spinella mentioned two promising new methods that are being researched and developed in Europe: Non-invasive PGT-A (NiPGT-A) and PGT for ploidy (Ploidy). These breakthroughs are driven by the rapid development of genetic sequencing technologies, opening new possibilities for reproductive healthcare.
NiPGT-A represents a breakthrough in preimplantation genetic testing, allowing for testing without the need for embryo biopsy, thus minimizing potential risks to the embryo. This method detects chromosomal abnormalities in embryos from the culture medium, providing greater convenience and safety. Meanwhile, PGT for ploidy (Ploidy) is an advanced test that accurately determines the number of chromosomes in the embryo, helping to select embryos with a complete chromosomal set, thereby reducing the risk of reproductive issues or birth defects.
Assoc Prof. Dr. Francesca Spinella also expressed her deep impression with the preimplantation genetic testing methods being used in Vietnam. She stated that the expertise and modern facilities of the labs, especially at GENTIS, are on par with leading genetic testing centers worldwide.
Assoc Prof. Dr. Francesca Spinella Visits and Works at GENTIS Lab
In addition to common tests like PGT-A, PGT-M, and PGT-SR, GENTIS is also focusing on researching and developing two breakthrough techniques: PGT-Next and PGT-Upgrade. PGT-Next is an advanced method that combines the features of both PGT-A and PGT-SR, with the added capability of detecting chromosomal number abnormalities such as polyploidy and haploidy in embryos. This improves diagnostic accuracy, minimizes the risk of pregnancy with embryos that have chromosomal abnormalities, and optimizes the chances of a healthy pregnancy.
PGT-Upgrade is a significant advancement in genetic diagnosis of embryos. In addition to detecting abnormalities in chromosome number (PGT-A) and structure (PGT-SR), PGT-Upgrade can identify balanced chromosomal translocations passed from parents to embryos. This method helps detect hidden risks that PGT-A and PGT-SR cannot diagnose, while also identifying genetic factors that could affect the health of future generations. PGT-Upgrade offers superior advantages in selecting healthy embryos for artificial reproduction, thereby improving IVF success rates.
Strengthening Relationships and Promoting Multilateral Cooperation Among Global Healthcare Organizations
Promising Collaboration Between GENTIS and GENOMA
Through her visit and discussions, Assoc. Prof. Dr. Francesca Spinella noted that Vietnam’s healthcare services, particularly in reproductive medicine, have significant potential for growth. She emphasized that this event not only provided an opportunity to exchange ideas on advancements in genetic testing but also served as a clear testament to the sustainable and strategic partnership between GENTIS and GENOMA, both members of the Eurofins family. The cooperation between GENTIS and GENOMA is not based solely on commercial interests but also on the shared commitment to scientific research and advanced technologies. Both organizations share values in improving reproductive health and providing accurate and reliable genetic testing services for families and healthcare professionals in their reproductive health journeys.
This collaboration also allows GENTIS to access the latest genetic testing technologies and implement them in Vietnam, enhancing the quality of reproductive healthcare services domestically and contributing to the development of the genetic testing industry in Southeast Asia. GENTIS’s clients will now benefit from advanced genetic testing services, which offer the opportunity for healthy childbirth and minimize risks during pregnancy.
[content_more] => [meta_title] => Breakthroughs in the Application of Genetic Testing in Reproductive Medicine Worldwide and in Vietna [meta_description] => During her visit and work in Vietnam, Assoc. Prof. Dr. Francesca Spinella, she mentioned that the collaboration between GENTIS and GENOMA will enhance multi-level development among global healthcare organizations, particularly in the area of genetic testi [meta_keyword] => GENTIS,pgt [thumbnail_alt] => [post_id] => 1275 [category_id] => 4 ) [6] => stdClass Object ( [id] => 1274 [id_crawler] => [category_product] => NULL [thumbnail] => gentis-6.jpg [album] => [url_video] => [is_status] => 1 [is_featured] => 0 [is_form] => 1 [displayed_time] => 0000-00-00 [program] => 0 [number] => 1 [viewed] => 0 [type] => [type_career] => [level] => [address] => [address_career] => [expiration_time] => 0000-00-00 [created_time] => 2025-01-11 08:29:18 [updated_time] => 2025-01-13 15:57:55 [files] => [salary] => [time] => [created_by] => 63 [is_table_content] => 1 [language_code] => en [slug] => learning-about-new-genetic-tests-in-reproductive-support-worldwide-and-their-application-in-europe-with-assoc-prof-dr-francesca-spinella [title] => Learning About New Genetic Tests in Reproductive Support Worldwide and Their Practical Application in Europe with Assoc. Prof. Dr. Francesca Spinella [description] => With the goal of updating knowledge to enhance the effectiveness of medical examination and treatment, as well as to introduce reproductive support techniques being applied in Europe, the GENTIS Genetic Counseling Center successfully organized the 5th edition of the Genetic Counseling Talkshow - Discussion with Experts. The theme was “Application of New Genetic and Genomic Testing in Reproductive Support Worldwide and Their Practical Use in Europe.” GENTIS was honored to have Assoc. Prof. Dr. Francesca Spinella (Senior Medical Information Specialist of Eurofins Genoma Group, Former Chair of the ESHRE PGT Consortium) and Dr. ThS. BSNT Đinh Thị Quỳnh Ngọc (GENTIS Genetic Counseling Center) as speakers. The program attracted widespread attention from doctors, specialists, and many audiences interested in reproductive support methods. [content] =>Speaking about the pre-implantation genetic testing (PGT) techniques currently used in Europe, Assoc. Prof. Dr. Francesca Spinella said: "Currently, there are three common types of pre-implantation genetic tests: PGT-A, PGT-SR, and PGT-M. PGT-A is used to detect chromosomal abnormalities, allowing the selection of embryos without chromosomal abnormalities for embryo transfer. PGT-M is a tool to detect genetic mutations that could be inherited from the parents, thereby preventing the transfer of embryos with genetic disorders. PGT-SR is a method capable of detecting structural chromosomal abnormalities of 5Mb or more in embryos, thus increasing the chances of achieving a successful pregnancy by selecting normal embryos."
In addition to the three conventional PGT tests, Assoc. Prof. Dr. Francesca Spinella also discussed two new methods: Non-invasive PGT-A (NiPGT-A) and PGT for Ploidy (Ploidy). “NiPGT-A provides the opportunity to test embryos without the need for biopsy, by analyzing DNA in the culture medium. Meanwhile, PGT for Ploidy helps detect the presence of specific chromosomal abnormalities in embryos, thus avoiding the transfer of these embryos." However, she also mentioned that more research is needed to further validate the effectiveness of these two methods.
Assoc. Prof. Dr. Francesca Spinella also addressed several audience questions, including the importance of genetic counseling in IVF procedures, criteria for selecting mosaic embryos for transfer, and especially the appropriate timing for performing PGT methods, especially PGT for Ploidy. She spent a lot of time discussing the advantages, practical applications, and outcomes that can be achieved by using the genetic testing methods currently applied in Europe.
Understanding the concerns of infertile couples about the cost of these procedures, Assoc. Prof. Dr. Francesca Spinella shared: "The new PGT tests are optimal methods, incorporating advanced techniques from pre-implantation genetic screening. Therefore, it is understandable that the costs of these tests are slightly higher. However, in the future, the cost of these tests may decrease due to rapid technological advancements and the widespread adoption of testing. For example, the first PGT tests had extremely high costs when they were first introduced, but over time, the costs have stabilized, allowing many patients to access this method."
Notably, during the conversation, Assoc. Prof. Dr. Francesca Spinella provided in-depth insights and timely answers, helping doctors, specialists, and viewers better understand the application of current pre-implantation genetic tests. The Talkshow program was a success, attracting thousands of views, numerous shares, and receiving a lot of support from the audience.
Before concluding the Talkshow, Assoc. Prof. Dr. Francesca Spinella shared that she was very impressed after visiting some PGT and IVF labs in Vietnam, particularly GENTIS. She further mentioned that she was impressed with the facilities and the quality of healthcare professionals in Vietnam. Additionally, Assoc. Prof. Dr. Francesca Spinella noted that “Vietnam’s healthcare services in general, and reproductive support in particular, have a lot of potential for development” and emphasized the collaborative relationship within the Eurofins family, both scientifically and commercially.
We hope that the insights shared by the experts during the Talkshow will be beneficial for doctors and the audience. GENTIS Genetic Counseling Center sincerely thanks the doctors, partners, experts, and clients for their participation. We will continue to organize more Genetic Counseling Talkshow programs to provide valuable information to the audience.
The event was attended by esteemed guests, including Prof. Dr. Nguyen Dinh Tao, President of the Hanoi Fertility Support Association; former Deputy Director of the Embryo Technology Center (now the Army Clinical Morphology Institute – Military Medical Academy); Prof. Tran Thi Phuong Mai, former Deputy Head of the Maternal and Child Health Department; Assoc. Prof. Dr. Nguyen Quang, President of the Vietnam Sexual Medicine Association, Director of the Male Health Center, Viet Duc Friendship Hospital, along with nearly 200 delegates who are leading experts and doctors from major hospitals and medical centers across the country. From the Hanoi Hospital for Male Health and Infertility, attendees included: Assoc. Prof. Dr. Le Thi Thu Hien – Medical Director of the Hospital; Dr. CKI Pham Van Huong – Deputy Medical Director, Head of the Assisted Reproductive Technology Department; Assoc. Prof. Nguyen Minh Duc, Head of the Assisted Reproductive Technology Laboratory; and Dr. Dinh Huu Viet - Head of the Male Health Department.
At the 5th Scientific Conference, alongside research presentations from leading experts from major hospitals and fertility centers, such as the report "Male Infertility: Current Challenges and Future Directions" by Assoc. Prof. Dr. Nguyen Quang, and "Disorders of Sexual Development and Reproductive Function" by Assoc. Prof. Dr. Vu Chi Dung, the Hanoi Hospital for Male Health and Infertility contributed three reports on highly practical topics: “Male Infertility from a Practical Perspective at the Hanoi Hospital for Male Health and Infertility” by Dr. Dinh Huu Viet; “Preparation of Severe Abnormal Sperm Samples in Assisted Reproduction” by Assoc. Prof. Nguyen Minh Duc; and “Genetic Testing Before Embryo Transfer in Male Infertility: When is it Necessary?” presented by Dr. Bui Thi Phuong Hoa, a genetics specialist. These three topics were synthesized and researched by doctors and embryologists to share knowledge and gather feedback from leading experts in genetics, male health, and reproductive support. The aim was also to provide new perspectives on male infertility treatment from genetic and embryological aspects in actual clinical practice.
Speaking at the conference, Assoc. Prof. Dr. Le Thi Thu Hien (Medical Director of the Hospital) stated, “In addition to our daily medical examination and treatment activities, the Hanoi Hospital for Male Health and Infertility is particularly focused on scientific research. Scientific research helps create reliable new knowledge, enhances treatment quality and safety for patients, and increases effectiveness at reasonable costs. Moreover, scientific research enables doctors and healthcare staff to continuously improve their knowledge and skills while addressing issues in their professional work, aiming to deliver the best outcomes for patients. We have been and are striving to excel in both medical treatment and scientific research to bring new breakthroughs to our nation's healthcare."
The conference successfully created an open forum for sharing experiences and knowledge. The enthusiastic participation of experts and doctors fostered a vibrant and beneficial discussion space, aiming to find new directions for the field of male health. The hospital expresses sincere gratitude to all speakers and esteemed delegates, experts, and doctors who contributed to the success of this conference.
[content_more] => [meta_title] => Gentis accompanies the Andrology and fertility hospital of Hanoi at the 5th Scientific Conference [meta_description] => On the morning of September 22, 2024, Hanoi Hospital for Male Health and Infertility (AF HANOI) successfully organized the "5th Scientific Conference.". GENTIS is honored to accompany the Hanoi Hospital for Male Health and Infertility as a sponsor, contr [meta_keyword] => Gentis [thumbnail_alt] => [post_id] => 1273 [category_id] => 4 ) )
GENTIS welcomes Illumina experts to visit and work
Dr. Pham Dinh Minh reported at the 7th Tzu Chi - Academia Sinica Biomedical Conference
Sperm DNA Test - An effective solution to help doctors diagnose male infertility
Which pregnant women should do Non-invasive prenatal testing?
GENTIS launches 2 new test packages: PGT NEXT and PGT UPGRADE
Breakthroughs in the Application of Genetic Testing in Reproductive Medicine Worldwide and in Vietnam
Learning About New Genetic Tests in Reproductive Support Worldwide and Their Practical Application in Europe with Assoc. Prof. Dr. Francesca Spinella
Gentis accompanies the Andrology and fertility hospital of Hanoiat the 5th Scientific
Quý khách vui lòng điền thông tin bên dưới để được hỗ trợ,
tư vấn một cách tốt nhất!
Xem Socolive trực tuyến tiếng Việt
Link Bóng Đá Lu miễn phí
Link Rakhoi TV bóng đá trực tuyến
Xem tructiep https://xoilaczll.tv/
Link trực tiếp MitomTV bình luận tiếng Việt https://f8betht.baby Xem tructiep https://uniscore.com/vi NEW88 NEW88 789BET 789BET 789BETQuý khách vui lòng điền thông tin bên dưới để được hỗ trợ,
tư vấn một cách tốt nhất!
